Real-world outcomes for advanced melanoma in the adjuvant and unresectable setting: Single-center registry analysis

Real-world outcomes for advanced melanoma in the adjuvant and unresectable setting: Single-center registry analysis

Saved in:

Bibliographic Details
Main Authors:	R. Staeger, J.M. Martínez-Gómez, E. Ramelyte, L. Kraehenbuehl, M.P. Levesque, R. Dummer, J. Mangana
Format:	Article
Language:	English
Published:	Elsevier 2024-01-01
Series:	EJC Skin Cancer
Online Access:	http://www.sciencedirect.com/science/article/pii/S2772611824001538
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Advanced Melanoma: Updated Results from Ongoing Trials
by: Egle Ramelyte, et al.
Published: (2024-10-01)

Real-World efficiency of pembrolizumab in metastatic melanoma patients following adjuvant anti-PD1 treatment
by: Michael Weichenthal, et al.
Published: (2024-12-01)

Real-world outcomes of adjuvant therapy in melanoma: an Italian referral center experience
by: G. Roccuzzo, et al.
Published: (2024-01-01)

Atypical spitzoid lesions: A molecular and histological analysis of two NTRK driven cases
by: M. Teufer, et al.
Published: (2024-01-01)

Real‐World nivolumab dosing patterns and safety outcomes in patients receiving adjuvant therapy for melanoma
by: Wolfram Samlowski, et al.
Published: (2023-02-01)

Adjuvant Therapy: Melanoma
by: Diwakar Davar, et al.
Published: (2011-01-01)

Infliximab in steroid-refractory immune-related hepatitis does not demonstrate hepatotoxicity and may shorten time on steroids
by: Reinhard Dummer, et al.
Published: (2024-07-01)

Efficacy of second-line treatment for gemcitabine-refractory unresectable pancreatic cancer in a real-world setting
by: Qianqian Wang, et al.
Published: (2025-07-01)

The RoMEO study: a real-world, observational, prospective investigation of dabrafenib and trametinib combination treatment in patients with BRAF V600 unresectable or metastatic cutaneous melanoma
by: L. Mortier, et al.
Published: (2024-01-01)

Real‐world experience of adjuvant immunotherapy for stages III–IV melanoma: A monocentric observational study
by: Manon Blaise, et al.
Published: (2025-06-01)

Comparing immunotherapy effectiveness for unresectable hepatocellular carcinoma: infiltrative versus non-infiltrative types in real-world settings
by: Chien-Ming Chiang, et al.
Published: (2025-01-01)

Adoptive TIL Transfer in the Adjuvant Setting for Melanoma: Long-Term Patient Survival
by: Amir Khammari, et al.
Published: (2014-01-01)

Korean medicine registry for allergic rhinitis in real-world settings (KOREA-R): a multicenter registry protocol
by: Boram Lee, et al.
Published: (2025-07-01)

Phase I study of pembrolizumab in combination with ibrutinib for the treatment of unresectable or metastatic melanoma
by: Yuan Yao, et al.
Published: (2025-02-01)

An update on adjuvant systemic therapies in melanoma
by: Evangeline Samuel, et al.
Published: (2019-11-01)

Updated outcomes of AdjuMel study: real-world data in patients with resected stage III-IV melanoma treated with adjuvant nivolumab in France
by: S. Dalle, et al.
Published: (2024-01-01)

Isolated chemohyperthermal perfusion of the liver with melphalan in the treatment of unresectable liver metastases with uveal melanoma
by: A. D. Kaprin, et al.
Published: (2021-12-01)

Adjuvant Proton Beam Radiation Therapy for Sinonasal Mucosal Melanoma
by: Jamie S. K. Takayesu, et al.
Published: (2025-02-01)

Tolerability and Effectiveness of Regorafenib Treatment in Patients with Unresectable Hepatocellular Carcinoma: Real-World Data from the United States
by: Finn RS, et al.
Published: (2025-02-01)

Quantitatively defined stromal B cell aggregates are associated with response to checkpoint inhibitors in unresectable melanoma
by: James W. Smithy, et al.
Published: (2025-04-01)

Patient treatment preferences in unresectable/metastatic BRAF-mutated melanoma: a qualitative study
by: T. Amaral, et al.
Published: (2024-01-01)

Efficacy of atezolizumab plus bevacizumab for unresectable HCC: Systematic review and meta-analysis of real-world evidence
by: Giulia Francesca Manfredi, et al.
Published: (2025-08-01)

Atezolizumab Plus Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma: Real-World Experience From a US Community Oncology Network
by: Cosgrove D, et al.
Published: (2025-04-01)

Gastric cancer hospital-based registry: real-world gastric cancer data from Latin America and Europe
by: B. Freile, et al.
Published: (2024-12-01)

Commentary: Real-World Insights into Adjuvant Immunotherapy after Esophagectomy
by: Min Hee Hong
Published: (2025-07-01)

First-line Nivolumab plus Ipilimumab in patients with advanced melanoma previously treated with adjuvant systemic therapy
by: K. Kisielewska, et al.
Published: (2024-01-01)

Melanoma Vaccines: Comparing Novel Adjuvant Treatments in High-Risk Patients
by: Joseph C. Broderick, et al.
Published: (2025-06-01)

High-Grade Pneumonitis Events in Patients With Unresectable, Locally Advanced NSCLC Treated With Definitive Chemoradiation Followed by Adjuvant Durvalumab
by: Ciani Ellison, MD, et al.
Published: (2024-12-01)

Real-world management and outcome of patients with pancreatic adenocarcinoma. Results of the Spanish RETUD gastrointestinal registry
by: T. Macarulla, et al.
Published: (2025-03-01)

Comparative Analysis of Pembrolizumab Dosing Schedules in the Adjuvant Treatment of Malignant Melanoma
by: Y. Ahmed, et al.
Published: (2024-01-01)

Innovations in Genicular Outcomes Registry (IGOR): protocol for a real-world registry study of treatments for knee osteoarthritis
by: Vinod Dasa, et al.
Published: (2024-12-01)

The updated Swiss guidelines for the treatment and follow-up of cutaneous melanoma
by: Johanna Mangana, et al.
Published: (2025-07-01)

MDM2 amplification in a real-world cohort of patients with biliary tract cancer from the Spanish RETUD gastrointestinal registry
by: A.J. Muñoz Martín, et al.
Published: (2025-06-01)

Real‐Life Cohort of Patients With Resected High‐Risk Melanoma Treated by Adjuvant Anti‐PD1 Therapy
by: Liza Benzoni, et al.
Published: (2025-03-01)

Real-life evidence of encorafenib plus binimetinib in patients with unresectable advanced or metastatic BRAFV600-mutant melanoma in Spain: the BECARE (GEM-2002) trial
by: Ainara Soria, et al.
Published: (2025-02-01)

Real-world treatment patterns and outcomes among patients with HER2-positive unresectable or metastatic breast cancer in China
by: Jiajia Huang, et al.
Published: (2025-05-01)

Interventional treatment combined with immunotargeted therapy in unresectable combined hepatocellular-cholangiocarcinoma: a real-world retrospective cohort study
by: Yan-Song Lin, et al.
Published: (2025-07-01)

Cadonilimab, a PD-1/CTLA-4 bispecific antibody in unresectable hepatocellular carcinoma: a real-world study
by: Yilin Wang, et al.
Published: (2025-04-01)

Economic evaluation of adverse events of dabrafenib plus trametinib versus nivolumab in patients with advanced BRAF-mutant cutaneous melanoma for adjuvant therapy in Germany
by: S Wahler, et al.
Published: (2021-01-01)

Clinical and economic analysis of treatment sequences with prolgolimab and BRAF/MEK inhibitors in adult patients with metastatic or unresectable cutaneous melanoma
by: S. K. Zyryanov, et al.
Published: (2024-02-01)